It’s an unusually eventful time for the bond market. Prices have been roiled by the United States’ trade war against the ...

Going forward, Celltrion is expected to continue its current strategy, aiming to have a total of 23 biosimilar products by 2030, covering therapeutic areas such as immunology and oncology. Leveraging ...